Touchstone Capital Inc. Takes Position in Johnson & Johnson $JNJ

Touchstone Capital Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the third quarter, Holdings Channel.com reports. The firm purchased 5,838 shares of the company’s stock, valued at approximately $1,082,000. Johnson & Johnson makes up about 0.6% of Touchstone Capital Inc.’s investment portfolio, making the stock its 28th biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. United Bank boosted its holdings in Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC increased its position in Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after purchasing an additional 692 shares during the period. Sovran Advisors LLC raised its holdings in Johnson & Johnson by 7.2% during the 2nd quarter. Sovran Advisors LLC now owns 6,323 shares of the company’s stock worth $985,000 after purchasing an additional 422 shares during the last quarter. Finally, Secure Asset Management LLC lifted its position in Johnson & Johnson by 8.2% during the 2nd quarter. Secure Asset Management LLC now owns 4,981 shares of the company’s stock valued at $761,000 after purchasing an additional 377 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $218.81 on Friday. The stock has a market cap of $527.18 billion, a P/E ratio of 21.12, a P/E/G ratio of 2.26 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $220.11. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a fifty day simple moving average of $205.82 and a 200 day simple moving average of $186.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.76 by $0.04. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $23.99 billion for the quarter, compared to analyst estimates of $23.73 billion. During the same period in the previous year, the company posted $2.42 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s payout ratio is currently 50.19%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several analyst reports. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Royal Bank Of Canada set a $240.00 target price on shares of Johnson & Johnson in a research report on Wednesday, December 17th. HSBC restated a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 10th. Finally, Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.